Nonsteroidal Anti-Inflammatory Drug Therapy and Gastric Side Effects

Drugs ◽  
1990 ◽  
Vol 40 (Supplement 5) ◽  
pp. 16-24 ◽  
Author(s):  
P. Dandona ◽  
J.Y. Jeremy
Keyword(s):  
Drug Therapy ◽  
Side Effects ◽  
Inflammatory Drug ◽  
Anti Inflammatory

Potential complications of nonsteroidal anti-inflammatory drug therapy

1989 ◽  
Vol 79 (12) ◽  
pp. 605-614
Author(s):  
GD Corrigan ◽  
L Pantig-Felix ◽  
IO Kanat
Keyword(s):  
Health Care ◽  
Patient Satisfaction ◽  
Drug Therapy ◽  
Side Effects ◽  
Mechanism Of Action ◽  
Drug Class ◽  
Inflammatory Drug ◽  
The Us ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

Since indomethacin was first marketed, some 40 years ago, the class of nonsteroidal anti-inflammatory drugs has grown larger than any other drug class in history. At present, there are at least 25 such drugs being used in the US and abroad, both clinically and in research. Despite their widespread use, their implications to health care are just beginning to be understood. The authors review updated theories on the mechanism of action, side effects, and drug interactions of nonsteroidal anti-inflammatory drug therapy. Proposed guidelines for monitoring their use are given. A more thorough understanding of the risks-to-benefits ratio is provided in an effort to achieve maximum patient satisfaction and safety.

General Practitioners' Evaluation of Side-Effects and Efficacy of Oxamethacin as Compared with Indomethacin

1980 ◽  
Vol 8 (2) ◽  
pp. 156-162 ◽  
Author(s):  
J Polderman ◽  
M Colon
Keyword(s):  
Clinical Trial ◽  
Drug Therapy ◽  
Side Effects ◽  
General Practitioners ◽  
Double Blind ◽  
Inflammatory Drug ◽  
Pathological Conditions ◽  
Maximum Duration ◽  
Double Blind Clinical Trial ◽  
Anti Inflammatory

Sixteen general practitioners conducted a multicentre double-blind clinical trial to compare oxamethacin (100 mg t.i.d.) with indomethacin (50 mg t.i.d.) for a maximum duration of 2 weeks. Each drug was administered to 339 patients suffering from various pathological conditions requiring a non steroidal anti-inflammatory drug. When focusing on patients without associated drug therapy, 126/250 patients (50%) presented a good response on inflammation under oxamethacin and 98/236 patients (42%) a good response under indomethacin (p < 10−2); 141/250 patients (56%) presented a good response on pain under oxamethacin and 117/236 (50%) under indomethacin (p<5.10−2). Side effects and complaints were reported by 34/250 patients (14%) under oxamethacin and by 67/236 (28%) under indomethacin (p < 5.10−5). Some patients stopped treatment because of side-effects: 14/250 (6%) under oxamethacin and 32/236 (14%) under indomethacin (p < 2.10−3).

Reducing pain in certain forms of obstetric pathology: nonsteroidal anti-inflammatory drugs (Сlinical lecture)

2017 ◽  
pp. 9-14
Author(s):  
L. Nazarenko ◽  
Keyword(s):  
Preterm Birth ◽  
Side Effects ◽  
Key Words ◽  
Clinical Efficacy ◽  
Premature Birth ◽  
Pain Syndrome ◽  
Inflammatory Drug ◽  
Threatened Abortion ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

The article discusses the pathogenetic basis for the use of non-steroidal anti-inflammatory drugs (NSPVP) in obstetric practice for the treatment of pain syndrome in women with threatened abortion and pathological preliminary period. Provided with modern views on the mechanisms of analgesic clinical efficacy, side effects NSPVP. Provides information about the place of NSPVP during pregnancy, the risks to the fetus, the positive aspects in the conduct of women at risk of preterm birth, the pathological preliminary period. Key words: nonsteroidal anti-inflammatory drug, pain, premature birth, preliminary period.

scholarly journals Involvement of Anti-Inflammatory, Antioxidant, and BDNF Up-Regulating Properties in the Antipsychotic-Like Effect of the Essential Oil of Alpinia Zerumbet in Mice: A Comparative Study With Olanzapine

2021 ◽  
Author(s):  
Fernanda Yvelize Ramos de Araújo ◽  
Adriano José Maia Chaves Filho ◽  
Adriana Mary Nunes ◽  
Gersilene Valente de Oliveira ◽  
Patrícia Xavier Lima Gomes ◽  
...  
Keyword(s):  
Weight Gain ◽  
Drug Therapy ◽  
Side Effects ◽  
Essential Oil ◽  
Negative Symptoms ◽  
Repeated Administration ◽  
Social Impairment ◽  
Standard Drug ◽  
Anti Inflammatory ◽  
Alpinia Zerumbet

Abstract The current drug therapy for schizophrenia effectively treats acute psychosis and its recurrence; however, this mental disorder’s cognitive and negative symptoms are still poorly controlled. Antipsychotics present important side effects, such as weight gain and extrapyramidal effects. The essential oil of Alpinia zerumbet (EOAZ) leaves presents potential antipsychotic properties that need further preclinical investigation. Here, we aimed to determine the effects of EAOZ in the prevention and reversal of schizophrenia-like symptoms (positive, negative, and cognitive) induced by ketamine (KET) repeated administration in mice and putative neurobiological mechanisms related to this effect. To this end, we evaluated antioxidant (GSH, nitrite levels), anti-inflammatory [interleukin (IL)-6], and neurotrophic [brain-derived neurotrophic factor (BDNF)] effects of this oil in hippocampal tissue. The atypical antipsychotic olanzapine (OLZ) was used as standard drug therapy. EOAZ, similarly to OLZ, prevented and reversed most KET-induced schizophrenia-like behavioral alterations, i.e., sensorimotor gating deficits and social impairment. EOAZ had a modest effect on the prevention of KET-associated working memory deficit. Compared to OLZ, EOAZ showed a more favorable side effects profile, inducing less cataleptic and weight gain changes. EOAZ efficiently protected the hippocampus against KET-induced oxidative imbalance, IL-6 increments, and BDNF impairment. In conclusion, our data add more mechanistic evidence for the anti-schizophrenia effects of EOAZ, based on its antioxidant, anti-inflammatory, and BDNF up-regulating actions. The absence of significant side effects observed in current antipsychotic drug therapy seems to be an essential benefit of the oil.

Sign in / Sign up

Export Citation Format

Share Document